Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective
- Author:
Thorsten Oliver GOETZE
1
;
Salah Eddin AL-BATRAN
;
Felix BERLTH
;
Arnulf Heinrich HOELSCHER
Author Information
- Publication Type:Review
- Keywords: Surgery; Multidisciplinary research; Basic research; Guideline
- MeSH: Combined Modality Therapy; Drug Therapy; Esophageal Neoplasms; Esophagogastric Junction; Humans; Incidence; Trastuzumab
- From:Journal of Gastric Cancer 2019;19(2):148-156
- CountryRepublic of Korea
- Language:English
- Abstract: Esophagogastric junction (EGJ) cancer is a solid tumor entity with rapidly increasing incidence in the Western countries. Given the high proportion of advanced cancers in the West, treatment strategies routinely employed include surgery and chemotherapy perioperatively, and chemoradiation in neoadjuvant settings. Neoadjuvant chemoradiation and perioperative chemotherapy are mostly performed in esophageal cancer that extends to the EGJ and gastric as well as EGJ cancers, respectively. Recent trials have tried to combine both strategies in a perioperative context, which might have beneficial outcomes, especially in patients with EGJ cancer. However, it is difficult to recruit patients for trials, exclusively for EGJ cancers; therefore, the results have to be carefully reviewed before establishing a standard protocol. Trastuzumab was the first drug for targeted therapy that was positively evaluated for this tumor entity, and there are several ongoing trials investigating more targeted drugs in order to customize effective therapies based on tissue characteristics. The current study reviews the multimodal treatment concept for EGJ cancers in the West and summarizes the latest reports.
